Actuate Therapeutics Inc Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Actuate Therapeutics Inc (ACTU) holds an ST Score of 33.6 out of 100 (C-), with its strongest factor being Forecast (A) and its weakest Profitability (F). Analysts rate ACTU Buy across 1 ratings with a $21.00 average price target (+22.1% vs the current $0.91).
- Strongest
- ForecastA
- Weakest
- ProfitabilityF
All factor grades
- ForecastA
- ValuationC+
- GrowthC+
- MomentumC-
- Financial StrengthD-
- ProfitabilityF
- Piotroski2/9
Contact
ACTU stock: frequently asked questions
What is ACTU's ST Score?
Actuate Therapeutics Inc (ACTU) has an ST Score of 33.6 out of 100, an overall grade of C-. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ACTU a buy, sell, or hold?
Wall Street's consensus rating on ACTU is Buy based on 1 analyst ratings. Our own ST Score grades it C- (33.6/100). This is data, not investment advice — always do your own research.
What is ACTU's valuation grade?
Actuate Therapeutics Inc (ACTU) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ACTU's growth grade?
Actuate Therapeutics Inc (ACTU) earns a growth grade of C+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ACTU's profitability grade?
Actuate Therapeutics Inc (ACTU) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ACTU's financial strength grade?
Actuate Therapeutics Inc (ACTU) earns a financial strength grade of D-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ACTU?
The average analyst price target for Actuate Therapeutics Inc (ACTU) is $21.00 from 1 analysts, which is +22.1% versus the recent price of $0.91.
What is ACTU's Piotroski score?
Actuate Therapeutics Inc (ACTU) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.